SPA
HRMY icon

Sherbrooke Park Advisers’s Harmony Biosciences HRMY Stock Holding History

Sherbrooke Park Advisers’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,693
Closed -$240K – 364
2025
Q3 		$240K Sell
8,693
-4,026
-32% -$139K 0.11% 329
2025
Q2 		$402K Buy
+12,719
New +$409K 0.17% 240
2024
Q3 		– Sell
-8,643
Closed -$261K – 1052
2024
Q2 		$261K Buy
+8,643
New +$260K 0.05% 676

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sherbrooke Park Advisers's HRMY Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Harmony Biosciences (HRMY) in Q4 2025, closing a stake of 8,693 shares — an estimated $240K sold.

Sherbrooke Park Advisers first reported a position in HRMY in Q2 2024 and held it in 3 quarters. The position peaked at $402K in Q2 2025. 325 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Harmony Biosciences position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 8,693 Harmony Biosciences shares in Q4 2025, an estimated $240K.
  • Sherbrooke Park Advisers first reported a position in Harmony Biosciences in Q2 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Harmony Biosciences position peaked at $402K in Q2 2025.
  • 325 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.